10-QPeriod: Q2 FY2025

CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2025

Filed July 31, 2025For Securities:CVS

Summary

CVS Health Corporation reported a significant increase in total revenues for the three and six months ended June 30, 2025, up 8.4% and 7.7% respectively, driven by growth across all segments, particularly in Premiums and Products. However, the quarter was impacted by substantial litigation charges, leading to a decrease in net income for the three-month period by 42.7% and a slight decline of 3.4% for the six-month period compared to the prior year. Despite revenue growth, increased operating expenses, largely attributable to these litigation charges and a loss on Accountable Care assets, also pressured operating income. Looking ahead, CVS Health faces ongoing challenges including declining medical membership in Medicare and individual exchange products, potential utilization pressures impacting its Health Care Benefits segment, and ongoing regulatory scrutiny on its PBM practices. The company plans to exit individual public health insurance exchanges in 2026. Despite these headwinds, the company is focused on cost savings initiatives and expects benefits from market disruptions in the retail pharmacy sector.

Financial Highlights

54 data points
Beta

Revenue

$98.92B

45.4% Gross Margin

Net Income

$1.02B

1.0% Net Margin

EPS (Diluted)

$0.80

Total Assets

$258.34B

Cash & Equivalents

$11.79B

Free Cash Flow

$1.29B

Financial Statements
Beta
Revenue$98.92B
Cost of Revenue$54.01B
Gross Profit$44.91B
Operating Expenses$96.53B
Operating Income$2.38B
Net Income$1.02B
EPS (Basic)$0.81
EPS (Diluted)$0.80
Shares Outstanding (Basic)1.27B
Shares Outstanding (Diluted)1.27B

Key Highlights

  • 1Total revenues increased by 8.4% to $98.9 billion for the three months ended June 30, 2025, and by 7.7% to $193.5 billion for the six months ended June 30, 2025, driven by growth in Premiums and Products revenue.
  • 2Net income attributable to CVS Health decreased by 42.7% to $1.02 billion for the three months ended June 30, 2025, compared to $1.77 billion in the prior year, largely due to significant litigation charges.
  • 3Operating income for the three months ended June 30, 2025, decreased by 21.8% to $2.38 billion, primarily impacted by $833 million in legacy litigation charges.
  • 4The Health Care Benefits segment saw a significant increase in total revenues by 11.6% and 167.1% in operating income for the three-month period, driven by government business and favorable risk adjustment estimates, despite a premium deficiency reserve of $471 million for its Group Medicare Advantage product line.
  • 5The Health Services segment experienced a decrease in operating income by 37.6% and adjusted operating income by 17.8% for the three months, impacted by a $291 million litigation charge and increased healthcare costs.
  • 6The Pharmacy & Consumer Wellness segment reported a 12.5% revenue increase but a 37.6% decrease in operating income for the three months, also significantly affected by a $542 million litigation charge related to the Omnicare long-term care business.
  • 7Net cash provided by operating activities decreased by 19.3% to $6.45 billion for the six months ended June 30, 2025, compared to $7.99 billion in the prior year.

Frequently Asked Questions

The primary driver for the decrease in net income for the three months ended June 30, 2025, was a significant increase in operating expenses, largely due to legacy litigation charges totaling $833 million related to two court decisions concerning the Company's past business practices. Additionally, a loss on Accountable Care assets and other factors contributed to the decline.

The Health Care Benefits segment demonstrated strong revenue growth of 11.6% for the three months ended June 30, 2025, driven by its Government business, particularly due to the impact of the Inflation Reduction Act on the Medicare Part D program. Operating income saw a substantial increase of 74.6%. However, the segment recorded a $471 million premium deficiency reserve for its Group Medicare Advantage product line due to continued utilization pressure. The segment's Medical Benefit Ratio (MBR) slightly increased, reflecting these pressures, but was partially offset by favorable risk adjustment estimates.

CVS Health's medical membership has seen a decline, particularly in its Medicare and individual exchange products. The company plans to exit the states in which Aetna operates on the individual public health insurance exchanges effective January 2026. Membership disruptions are expected to cause volatility in financial results. While Commercial ASC membership saw an increase, it was not enough to offset declines in other areas.

CVS Health is facing multiple lawsuits and investigations concerning its Pharmacy Benefit Management (PBM) practices, including those from the FTC and various state Attorneys General, related to drug pricing and rebate arrangements. These proceedings, along with others such as the Omnicare litigation, have resulted in significant litigation charges and are expected to continue to impact operating expenses and potentially create financial risks. The company is actively defending itself in these matters.